Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by Desjardins Global Asset Management Inc.

Desjardins Global Asset Management Inc. grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 15.2% in the 4th quarter, Holdings Channel reports. The firm owned 8,123 shares of the company’s stock after acquiring an additional 1,070 shares during the quarter. Desjardins Global Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $85,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Money Concepts Capital Corp bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $25,000. Quilter Plc bought a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $3,103,125,000. Tower Research Capital LLC TRC grew its holdings in shares of Teva Pharmaceutical Industries by 1,729.5% during the third quarter. Tower Research Capital LLC TRC now owns 3,787 shares of the company’s stock valued at $39,000 after purchasing an additional 3,580 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 92.3% during the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock valued at $46,000 after purchasing an additional 2,180 shares during the last quarter. Finally, Signaturefd LLC grew its holdings in shares of Teva Pharmaceutical Industries by 90.8% during the third quarter. Signaturefd LLC now owns 5,032 shares of the company’s stock valued at $51,000 after purchasing an additional 2,394 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TEVA. The Goldman Sachs Group upped their target price on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Monday, February 5th. Piper Sandler raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $12.00 to $19.00 in a report on Monday, February 12th. Barclays increased their price objective on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Jefferies Financial Group raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and increased their price objective for the stock from $10.00 to $14.00 in a report on Tuesday, January 23rd. Finally, JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective for the company in a report on Friday, March 8th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.78.

Insiders Place Their Bets

In other news, EVP Mark Sabag sold 100,000 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the sale, the executive vice president now owns 382,590 shares in the company, valued at approximately $5,172,616.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Mark Sabag sold 100,000 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the sale, the executive vice president now owns 382,590 shares in the company, valued at approximately $5,172,616.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Eric Drape sold 173,261 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $13.05, for a total value of $2,261,056.05. Following the completion of the sale, the vice president now owns 1 shares of the company’s stock, valued at approximately $13.05. The disclosure for this sale can be found here. Insiders sold 390,738 shares of company stock worth $5,132,766 over the last ninety days. Company insiders own 0.62% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 0.6 %

TEVA opened at $12.86 on Friday. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02. Teva Pharmaceutical Industries Limited has a 1-year low of $7.09 and a 1-year high of $14.47. The business has a 50 day moving average price of $13.50 and a two-hundred day moving average price of $11.25.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.25. The firm had revenue of $4.46 billion during the quarter, compared to the consensus estimate of $3.97 billion. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. Research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.